In March 2022, the French Health Products Agency (ANSM) announced that the summary of product characteristics (SmPC) for proprietary drugs based on donepezil (Aricept0 or other brands), a cholinesterase inhibitor used in Alzheimer's disease, would carry an additional warning concerning prolongation of the electrocardiographic QT interval (1). QT interval prolongation carries a risk of torsades de pointes, a specific type of acute ventricular tachycardia which is sometimes fatal (2).
展开▼
